Research News
View articles by month and year
-
Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.
-
Herceptin-Tykerb-Chemo Combo Before Surgery May Help Treat Early-Stage HER2-Positive Disease
Early results suggest that a combination of four medicines given BEFORE surgery to treat HER2-positive, early-stage breast cancer may be a good way to weaken and destroy breast cancer cells.
-
Herceptin More Effective Than Tykerb When Given Before Surgery
Research suggests that Herceptin is more effective than Tykerb in a neoadjuvant regimen for early-stage or locally-advanced HER2-positive breast cancer.
-
Herceptin May Help Treat Small, Early-Stage HER2-Positive Breast Cancers
Research suggests that Herceptin may be able to reduce the risk of recurrence of early-stage, HER2-positive breast cancers that are smaller than 1 cm and haven't spread to the lymph nodes.
-
Herceptin Effectiveness Not Affected by Obesity
A small study found that Herceptin worked equally well in obese and non-obese women diagnosed with HER2-positive, metastatic breast cancer.
-
Herceptin Works Well in Older Women Diagnosed with HER2-Positive, Metastatic Disease
A small study suggests that older women diagnosed with HER2-positive, metastatic breast cancer can benefit from Herceptin treatment.
-
Experimental T-DM1 May Help Treat Metastatic, HER2-Positive Disease
A small, early study suggests that T-DM1, an experimental medicine, may be a better first treatment for women diagnosed with metastatic, HER2-positive breast cancer than a combination of Herceptin and Taxotere.
-
Herceptin-Avastin-Taxotere Combo Can Help Treat Metastatic HER2-Positive Breast Cancer
A small, very early study found that about 78% of women diagnosed with metastatic, HER2-positive breast cancer got some benefit from a combination of Herceptin, Avastin, and Taxotere as a first treatment.
-
Afinitor May Make Metastatic Breast Cancer Start Responding to Other Medicines Again
A small, early study suggests that Afinitor, a targeted therapy medicine, can make HER2-positive, metastatic breast cancers that have stopped responding to Herceptin and Taxol start responding to those treatments again.
-
Experimental Combo Shows Promise for Treating Metastatic HER2-Positive Cancer
A very small, very early study suggests that a combination of Herceptin and Afinitor may help treat HER2-positive, metastatic breast cancers that have stopped responding to many other treatments.
